Inventor · disambiguated record
Jinsong Ni
Also filed as: NI JINSONG
23 granted patents·10 pending applications·124 citations·filing 2002–2024
95Inventor score
Top patents by PatentIndex Score
33 records- 0197US11191751B1Topical ophthalmological atropine free base compositionsADS THERAPEUTICS LLC·Filed 2021·Granted Dec 7, 2021·17 cites·12 claims
- 0297US9987223B2Compositions and methods for treating pterygiumCLOUDBREAK THERAPEUTICS LLC·Filed 2017·Granted Jun 5, 2018·19 cites·24 claims
- 0397US9980901B2Compositions and methods for treating pterygiumCLOUDBREAK THERAPEUTICS LLC·Filed 2016·Granted May 29, 2018·16 cites·20 claims
- 0496US10149820B2Compositions and methods for treating pterygiumCLOUDBREAK THERAPEUTICS LLC·Filed 2018·Granted Dec 11, 2018·8 cites·11 claims
- 0595US10688092B2Compositions and methods of using nintedanib for improving glaucoma surgery successCLOUDBREAK THERAPEUTICS LLC·Filed 2019·Granted Jun 23, 2020·9 cites·27 claims
- 0694US12491183B2Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularizationADS THERAPEUTICS LLC·Filed 2024·Granted Dec 9, 2025·1 cites·13 claims
- 0794US10980741B2Compositions and methods for treating pterygium recurrenceCLOUDBREAK THERAPEUTICS LLC·Filed 2018·Granted Apr 20, 2021·5 cites·19 claims
- 0893US12186424B2Compositions and methods for treating pterygium recurrenceCLOUDBREAK THERAPEUTICS LLC·Filed 2021·Granted Jan 7, 2025·2 cites·6 claims
- 0992US12070501B1Topical ophthalmological compositionsADS THERAPEUTICS LLC·Filed 2022·Granted Aug 27, 2024·2 cites·15 claims
- 1092US10149819B2Compositions and methods for treating hyperemiaCLOUDBREAK THERAPEUTICS LLC·Filed 2018·Granted Dec 11, 2018·3 cites·11 claims
- 1191US11007214B2Compositions and methods for treating eye diseasesCLOUDBREAK THERAPEUTICS LLC·Filed 2020·Granted May 18, 2021·2 cites·10 claims
- 1290US12485177B2Topical ophthalmological compositionsADS THERAPEUTICS LLC·Filed 2024·Granted Dec 2, 2025·1 cites·14 claims
- 1390US11246864B2Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularizationADS THERAPEUTICS LLC·Filed 2017·Granted Feb 15, 2022·3 cites·10 claims
- 1490US10335408B2Compositions and methods of using nintedanib for improving glaucoma surgery successCLOUDBREAK THERAPEUTICS LLC·Filed 2018·Granted Jul 2, 2019·6 cites·27 claims
- 1588US2025262148A1Compositions and methods for treating pterygium recurrenceCLOUDBREAK THERAPEUTICS LLC·Filed 2024·Application pending·0 cites
- 1687US12156873B2Composition for treating ocular hyperemia and a method for treating ocular hyperemia with the sameADS THERAPEUTICS LLC·Filed 2019·Granted Dec 3, 2024·2 cites·7 claims
- 1787US11666533B2Emulsion formulations of multikinase inhibitorsCLOUDBREAK THERAPEUTICS LLC·Filed 2021·Granted Jun 6, 2023·1 cites·9 claims
- 1885US12214049B2Anti-angiogenic antibody-drug conjugatesADS THERAPEUTICS LLC·Filed 2020·Granted Feb 4, 2025·1 cites·15 claims
- 1984US11166977B2Compositions for treating meibomian gland dysfunctionADS THERAPEUTICS LLC·Filed 2020·Granted Nov 9, 2021·1 cites·2 claims
- 2082US6864282B29,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucomaALLERGAN INC·Filed 2002·Granted Mar 8, 2005·24 cites·37 claims
- 2178US11911379B2Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularizationADS THERAPEUTICS LLC·Filed 2022·Granted Feb 27, 2024·0 cites·22 claims
- 2277US10744153B1Compositions and methods for treating meibomian gland dysfunctionCLOUDBREAK THERAPEUTICS LLC·Filed 2019·Granted Aug 18, 2020·1 cites·12 claims
- 2377US2025161300A1Composition for treating ocular hyperemia and a method for treating ocular hyperemia with the sameADS THERAPEUTICS LLC·Filed 2024·Application pending·0 cites
- 2474US2023381103A1Emulsion formulations of multikinase inhibitorsCLOUDBREAK THERAPEUTICS LLC·Filed 2023·Application pending·0 cites
- 2567US2021315815A1Emulsion formulations of multikinase inhibitorsCLOUDBREAK THERAPEUTICS LLC·Filed 2019·Application pending·0 cites
- 2665US2023355594A1Topical ophthalmological compositionsADS THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 2763US2025115596A1Esters of 8-methyl-8-azabicyclo[3.2.1] octan-3-yl 3-hydroxy-2-phenylpropanoateADS THERAPEUTICS LLC·Filed 2023·Application pending·0 cites
- 2857US10835617B2VEGF antibody-drug conjugatesNI JINSONG·Filed 2017·Granted Nov 17, 2020·0 cites·4 claims
- 2957US2023398233A1Ocular antibody-drug conjugatesADS THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 3056US2024216337A1Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugsADS THERAPEUTICS LLC·Filed 2022·Application pending·0 cites
- 3154US2023210770A1Topical ophthalmological compositions and methods for treating abnormal angiogenesisADS THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 3253US2022331310A1Methods for alleviating pterygium-associated worry about eye appearanceCLOUDBREAK THERAPEUTICS LLC·Filed 2020·Application pending·0 cites
- 3348US11179388B2Topical composition for treating rosacea and a method for treating rosacea with the sameWHITCUP SCOTT·Filed 2018·Granted Nov 23, 2021·0 cites·5 claims
Join the waitlist — get patent alerts
Get an alert when Jinsong Ni files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →